The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / TRK / ALK / RET / EGFR Inhibitors, Clinical Trial Outcomes, Mechanisms of Resistance, and Safety Profiles

332 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login
2019 Lung Cancer and Head & Neck Cancer Symposium